WhatistheSymbol
Guerbet trades in the stock market under the ticker symbol of GBT. Search for the ticker of any public company above using the 'Get Ticker' search in red.

Who is Guerbet?


Warning: fopen(/home/whatist/public_html/symbol/cache/scraperDScache_getCompanyDetails_GBT) [function.fopen]: failed to open stream: Permission denied in /home/whatist/public_html/symbol/classes/class.cache.php on line 66
1,485 Employees
Last Reported Date: 08/1/14
Founded in 1901
Last €34.82 EUR
Change Today +0.02 / 0.06%
Volume 1.1K
As of 11:35 AM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

guerbet (GBT) Snapshot

Open
€34.80
Previous Close
€34.80
Day High
€34.93
Day Low
€34.80
52 Week High
09/11/14 - €45.52
52 Week Low
02/4/14 - €22.95
Market Cap
424.8M
Average Volume 10 Days
10.2K
EPS TTM
€1.90
Shares Outstanding
12.2M
EX-Date
06/2/14
P/E TM
18.3x
Dividend
€0.50
Dividend Yield
1.44%
Request Investor Kit
GBT:FP Advanced Stock Chart

Related News

No related news articles were found.

guerbet (GBT) Related News

No Related News Found

guerbet (GBT) Key Developments

Guerbet Announces Board Changes

The Board of Directors of Guerbet has co-opted Céline Lamort to the Board. The decision will be submitted to ratification at Guerbet's next Annual General Meeting of Shareholders on 29 May 2015. This appointment follows the resignation of Olivier Guerbet from the Board of Directors. Céline Lamort has ten years professional experience in the chemical industry where she has occupied various functions within production, maintenance and supply chain in the Netherlands and United States. Since 2013 she has been Operations Manager with Royal DSM N.V.

Guerbet Sa Announces Consolidated Revenue Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Annual Revenue Guidance for Full Year of 2014

Guerbet SA announced consolidated revenue results for the third quarter and nine months ended September 30, 2014. For the third-quarter, the company reported EUR 99.9 million in 2014 sales, up 3.4% at constant exchange rates, benefiting in particular from the pricing strategy for the X-Ray and MRI segments. For, the nine-month period ended September 30, 2014, the company reported sales were EUR 302.5 million compared to EUR 288.4 million for the same period a year ago, excluding currency effects, revenue reached EUR 306.0 million, up 6.1%. For the annual the company targets EUR 412 million (+/- 2%) at constant exchange rates in revenue for 2014 and an operating margin of 9%-10% (current operating income /reported sales).

Guerbet Receives FDA's Drug Shortage Assistance Award

Guerbet has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration for its assistance in preventing or alleviating a drug shortage. Guerbet is being recognized for its efforts related to the shortage of Ethiodol (ethiodized oil) injection, including acquiring the new drug application, submitting several post-approval supplements to restart manufacturing with acceptable compliance records, and to market the product for a well-known and medically necessary indication in the United States. These actions by Guerbet resolved a critical drug shortage affecting patients with cancer. Ethiodol (ethiodized oil) injection, now under the tradename of Lipiodol, is an oil-based radiopaque contrast agent used to image tumors in patients with certain types of cancer. Through the Drug Shortage Assistance Award program, FDA recognizes companies for making a substantial contribution to preventing or alleviating a critical drug shortage. Drug shortages pose a substantial public health threat, delaying, and in some cases even denying, critically needed care for patients. Working with drug manufacturers, the FDA helped prevent over 280 drug shortages in 2012 and 170 in 2013. There were 44 new drug shortages in 2013, down from 117 new drug shortages in 2012. Two key prevention strategies have helped drive this significant decrease in new shortages: early notification and a focus on quality manufacturing. FDA is committed to working with companies, like Guerbet, to prevent and mitigate drug shortages.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GBT:FP €34.82 EUR +0.02

GBT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €120.46 EUR +0.40
Covidien PLC $101.00 USD +0.46
Mallinckrodt PLC $92.22 USD +0.58
 

Industry Analysis

GBT

Industry Average

Valuation GBT Industry Range
Price/Earnings 17.3x
Price/Sales 1.0x
Price/Book 1.6x
Price/Cash Flow 8.3x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

No related news found for this Guerbet.
  • 0
  • 0
  • 0

Get our Stock Market & Financial Investment news alerts in your inbox

Read our full disclaimer and privacy policy